Introduction
============

Acne vulgaris is the most common dermatologic disorder. It affects approximately 85% of individuals aged between 12 and 24 years at some time ([@b8]). Various modalities have been performed for acne treatments, eg, topical and oral antibiotics, retinoic acids, and phototherapies ([@b1]; [@b6]; [@b17]). In phototherapies, blue light sources ([@b15]; [@b13]; [@b7]) and photodynamic therapy (PDT) using topical 5-aminolevulinic acid (ALA-PDT) ([@b4]) have been reported to be effective for acne vulgaris. Blue light is a theoretically effective phototherapy since exposure to blue visible light induces photoexcitation of porphyrins from *Propionibacterium acnes*, singlet oxygen production, and subsequent bacterial destruction ([@b7]). ALA-PDT utilizes visible light-induced phototoxic reaction of ALA-derived protoporphyrin IX (PpIX) accumulated in the target lesions of acne ([@b4]).

Recent reports demonstrate that laser therapies including 532-nm potassium titanyl phosphate laser, 585-nm pulsed dye laser, 1450-nm diode laser, and 1540-nm Er:glass laser are clinically effective in acne vulgaris ([@b2]; [@b9]; [@b11]). We performed an open study of a newly-developed 1450 nm diode laser as phototherapy of acne vulgaris. This diode laser was shown to be effective and well tolerated by acne patients, suggesting that this diode laser therapy could be a possible new treatment modality for acne.

Patients and methods
====================

Patients
--------

This study was an open clinical trial performed at our department from December 2005 to June 2006. Twenty-seven female patients with mild to moderate acne lesions involving the face and/or the back and/or the chest participated in this study. Mild to moderate acne was determined according to the definition by [@b3]). Patients had to have between 15 and 100 inflammatory lesions and/or between 15 and 100 noninflammatory lesions and no more than 3 nodules to be included ([@b3]). The average age was 23 years (range 16--34). No medication was administered during the 4 weeks prior to the study. The aims of the study were explained to the patients and informed consent was given.

Treatment protocol
==================

A 1450-nm diode laser (Smoothbeam™, Candela Corporation, Wayland, MA, USA) ([Figure 1](#fig1){ref-type="fig"}) was used for all treatments. This apparatus with the dynamic cooling device emitted light at 1450 nm with repetition rate of 1 Hz and pulse duration of 210 ms. Treatment fluence was 12.5 J/cm^2^ with a spot size of 6 mm. Each patient received treatments up to five times with a two week interval; other therapies were prohibited during this time. Both eyes were protected with an eyeglass to prevent unexpected adverse effects of the light during this treatment.

![The apparatus of 1450-nm diode laser with a dynamic cooling device.](tcrm0301-205-01){#fig1}

Clinical assessment was performed 5 times during the trial period (0, 2, 4, 6, 8, and 10 weeks). First, the number of lesions, eg, papules, pustules, cysts, and nodules, was counted. The secondary criterion was the investigator's global improvement rating on a five-point scale (−1, worsened; 0, unchanged; 1, improved; 2, markedly improved; and 3, resolved). Tolerance was assessed by asking patients about any signs or symptoms of adverse reactions.

Results
=======

Patients
--------

Twenty-seven female patients were recruited for the study. One patient discontinued treatment after the first treatment due to an adverse effect of vesicle formation. Four patients stopped after the second treatment, 4 patients stopped after the third, and 5 stopped after the fourth. Eleven patients stopped because skin lesions improved, while two stopped for nonmedical reasons after the second treatment. The numbers of lesions (mean ± standard deviation \[SD\]) before the treatment were 23.8 ± 18.1.

Clinical efficacy
-----------------

The number of lesions before treatment was 23.8 ± 18.1 (mean ± SD) (n=27). The number of lesions were: 20.5 ± 14.1 at 2 weeks after 1 treatment (n=27); 17.1 ± 13.9 at 4-weeks after 2 treatments (n=26); 13.5 ± 12.9 at 6 weeks after 3 treatments (n=22); 11.5 ± 10.1 at 8 weeks after 4 treatments (n=18); and 8.8 ± 7.5 at 10 weeks after 5 treatments (n=13). Diode laser therapy in our study achieved a marked reduction of lesions by 13.9%, 28.2%, 43.3%, 51.7%, and 63.0%, respectively ([Figure 2](#fig2){ref-type="fig"}). This improvement without statistically significance in Student's t-test showed a positive trend. Assessment of efficacy by the investigators showed that 96% of the patients had improved after 5 treatments, while 4% demonstrated an "unchanged" state ([Table 1](#tbl1){ref-type="table"}). Clinical pictures of two patients with marked improvement are shown in [Figures 3](#fig3){ref-type="fig"}--[5](#fig5){ref-type="fig"}. As seen in the figures, laser therapy with a 1450-nm diode laser was effective for cysts and nodules as well as papules and pustules.

![Counts of lesions (mean percentage reduction).](tcrm0301-205-02){#fig2}

![Case 1 (female, 20 years) with marked clinical improvement. A, before, and B, after the treatment.](tcrm0301-205-03){#fig3}

![Case 2 (female, 28 years) with marked clinical improvement. A, before, and B, after the treatment.](tcrm0301-205-04){#fig4}

![Case 3 (female, 21 years) with marked clinical improvement. A, before, and B, after the treatment.](tcrm0301-205-05){#fig5}

###### 

Physician\'s overall ratings for the response of inflammatory acne

  Rating              Number (%)
  ------------------- ------------
  Worsened            0 (0%)
  Unchanged           1 (4%)
  Improved            18 (67%)
  Markedly improved   6 (22%)
  Resolved            2 (7%)
  Total               27 (100%)

Tolerability
------------

Only one patient discontinued treatment due to vesicle formation as an adverse effect, which resolved without pigmentation or scarring. All patients felt pain during the irradiation. Two patients felt moderate pain and 25 felt slight pain. This pain was transient and needed no treatment. No patients discontinued the study because of the pain from this modality.

Discussion
==========

The 1450-nm diode laser in our study demonstrated a marked effect on mild to moderate acne lesions and was well tolerated. The reduction of number of skin lesions was 51.7% at 8 weeks and 63.0% at 10 weeks. Ninety-six percent of patients showed improvement by week 10 although 4% of patients were unchanged. Only one patient showed vesicle formation following no pigmentation or scarring. [@b2]) also reported minimal adverse effects from this diode laser therapy were transient erythema and edema. The 1450-nm diode laser may therefore be added to the panel of phototherapy used for acne treatment.

The 1450-nm laser with a dynamic cooling device has received Food and Drug Administration approval for the treatment of acne, atrophic acne scars, and fine wrinkles ([@b11]). The light at 1450 nm in the infrared spectrum corresponds to the peak of absorption spectrum of water in the dermis, which indicates the target chromophore to be collagen and sebaceous gland in the mid dermis. Histopathological studies reveal that this laser causes thermal damage to the collagen ([@b12]; [@b16]) and sebaceous glands ([@b12]). This laser is clinically effective for atrophic acne scar ([@b16]) and sebaceous hyperplasia ([@b10]). We hypothesize that the 1450-nm diode laser may remodel the collagen, form new collagen, and suppress the activity of sebaceous glands following an improvement of acne and acne scar tissue.

Blue light therapy has fewer effects on comedones than on inflammatory papules and pustules ([@b15]; [@b13]; [@b7]). Moreover, blue light emits the light of 415 nm that does not penetrate into the deep dermis, indicating blue light to be less effective for deeper acne lesions, eg, nodules and cysts. ALA-PDT is effective for acne vulgaris with significant side effects such as transient hyperpigmentation, superficial exfoliation, and crusting ([@b4]). The techniques of topical ALA-photodynamic therapy for skin disorders have not been optimally established since inhomogenous distribution or lack of selective accumulation of ALA-derived PpIX ([@b14]). Diode laser in our study was effective for nodules and cysts as well as papules and pustules with minimal adverse effects. Moreover, this laser therapy shows significant long-term clinical remission after treatment ([@b5]). The 1450-nm diode laser may therefore have some advantages over blue light therapy and ALA-PDT.

In conclusion, our study demonstrated that 1450-nm diode laser might be a treatment modality for mild to moderate acne.
